2026 American Society of Clinical Oncology (ASCO)
ASCO 2026 Prostate Cancer
- ASCO 2026: Prognostic Value of PSA Nadir and Meta-Analysis
- ASCO 2026: TRIPLE-SWITCH (SWOG/CCTG-PR26): A Randomized Phase III Clinical Trial for the Addition of Docetaxel to APRIs in Patients with mCSPC and Suboptimal PSA Response
- ASCO 2026: MRI Study: UMIN 000009823 – a Prospective Study of mpMRI-Guided Salvage Radiotherapy with Lesion-Directed Dose Escalation After Radical Prostatectomy: 10 Year Follow-up Results
- ASCO 2026: OPTION-DDR CCTG-PR-25: A Randomized Phase III Trial Investigating Platinum and Taxane Chemotherapy in mCRPC Patients with Alterations in DDR Genes
- ASCO 2026: Discussant - Moving Beyond Beta-Emitters: The Next Generation Radioligand Therapies in Prostate Cancer
ASCO 2026 Bladder Cancer
- ASCO 2026: Clinical Outcomes with ERBB2 Gene Amplification and Activating Mutations in MIBC Patients Treated with Neoadjuvant Chemotherapy
- ASCO 2026: Impact of FGFR3 Pathway Activation in Patients with MIBC Treated with Neoadjuvant Chemotherapy
- ASCO 2026: Rethinking the Role of Tumor Size in Bladder Preservation: Comparing Survival Outcomes of Radical Cystectomy and Trimodal Therapy
- ASCO 2026: Selective Bladder-Sparing Trial with Sasanlimab as Maintenance Treatment Based on Clinical Response to Neoadjuvant Treatment in Molecularly Categorized MIBC Patients: SASAN-SPARING Trial
- ASCO 2026: TROPION-Urothelial03: A Phase 2/3 Study of Datopotamab Deruxtecan + Platinum Based Chemotherapy versus Gemcitabine + Platinum Based Chemotherapy
ASCO 2026 Kidney Cancer
- ASCO 2026: Ultrasensitive ctDNA Detection and Molecular Clearance as a Prognostic and Predictive Marker in Advanced RCC
- ASCO 2026: Cabozantinib + Nivolumab versus Sunitinib in Patients with Advanced RCC and Bone Metastasis: Updated Subgroup Analysis of the Phase 3 CheckMate-9ER Trial
- ASCO 2026: Cabozantinib + Nivolumab versus Sunitinib in Patients with Advanced RCC and Liver Metastasis: Subgroup Analysis of the Phase 3 CheckMate-9ER Trial
- ASCO 2026: AI-Augmented Analysis of Quantitative ctDNA Burden and Longitudinal Kinetics to Identify Prognostic Risk Stratification in Metastatic Clear Cell RCC
- ASCO 2026: Final Results of a Phase 2 Trial of Cabozantinib + Nivolumab in Patients with Non Clear Cell RCC
ASCO 2026 Testicular and Penile Cancer
ASCO 2026 Upper Tract Urothelial Carcinoma
- ASCO 2026: Advancing Treatment of Low Grade Upper Tract Urothelial Carcinoma with Padeliporfin Vascular Targeted Photodynamic Therapy (VTP): The ENLIGHTED Phase 3 Trial
- ASCO 2026: Phase II Study of Frontline Gemcitabine, 5-Flurouracil/leucovorin, and Cisplatin in Advanced Urachal and Non-Urachal Urinary Tract Adenocarcinoma